Company profile: ReNAgade Therapeutics
1.1 - Company Overview
Company description
- Provider of RNA therapeutic platforms, offering RNA delivery systems to target previously inaccessible cells, an RNA coding platform (with Orna Therapeutics) for reprogramming cells, proprietary gene editing technology for permanent gene correction, and an all-RNA Gene Therapy 2.0 platform enabling exon and large gene insertions.
Products and services
- Gene Editing Technology: Proprietary system enabling permanent correction of defective genes to facilitate curative therapies, engineered for durable genetic repair across applicable disease contexts
- Gene Therapy 2.0 Platform: Platform-scale all-RNA system enabling exon or large gene insertions, engineered to advance gene therapy by supporting larger insertion events to produce new medications
- RNA Delivery Systems: Custom-engineered portfolio delivering RNA to previously inaccessible cells, expanding addressable diseases by transporting therapeutic RNA into cell types historically unreachable
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ReNAgade Therapeutics
Oncotelic Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics, developing RNA therapeutics and small molecule drugs against cancer and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncotelic Therapeutics company profile →
DNA Therapeutics
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development as a privately held company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Therapeutics company profile →
Alnylam
HQ: United States
Website
- Description: Provider of RNA interference (RNAi) therapeutics, focused on discovery, development and commercialization for rare genetic diseases; pipeline includes investigational genetic medicines and RNAi-based treatments for cardio-metabolic, infectious, central nervous system and ocular diseases; offers products for hereditary ATTR (hATTR) amyloidosis with polyneuropathy and related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alnylam company profile →
Kriya Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kriya Therapeutics company profile →
GenVec
HQ: United States
Website
- Description: Provider of differentiated, proprietary biopharmaceutical technologies for the creation of therapeutics and vaccines, developing and commercializing product candidates through collaborations with leading companies and organizations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenVec company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ReNAgade Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ReNAgade Therapeutics
2.2 - Growth funds investing in similar companies to ReNAgade Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ReNAgade Therapeutics
4.2 - Public trading comparable groups for ReNAgade Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →